Researchers from North Carolina State University have synthesized an analog of lipoxazolidinone A, a small molecule that is effective against drug-resistant bacteria such as MRSA. This molecule, a new synthetic compound inspired by a natural product, could be a useful chemical tool for studying other Gram-positive infections and may have implications for future drug creation.
Lipoxazolidinone A is a natural product which had been previously isolated from bacteria living in marine sediments. It is a secondary metabolite – a small molecule produced by the bacteria that isn’t key to its survival but is produced for a secondary purpose, like defense. When lipoxazolidinone A was initially isolated, researchers noted that it seemed effective against Gram-positive bacteria, like MRSA.
NC State chemist Joshua Pierce aimed to confirm those original findings and understand how the molecule’s structure correlated to its function; in short, he wanted to recreate the molecule to see what portions were directly responsible for its anti-microbial properties and then potentially improve upon that structure.
Pierce, along with current NC State graduate student Kaylib Robinson and former students Jonathan Mills and Troy Zehnder, used novel chemical tools to synthesize lipoxazolidinone A in the lab. They were able to confirm that its chemical structure matched what the initial researchers had indicated, then they worked to identify the portion of the molecule that was responsible for the activity against Gram-positive bacteria. Their result was a compound with improved potency, JJM-35.
They tested JJM-35 against a panel of resistant and non-resistant bacteria. When tested against MRSA in vitro, they found that the synthesized molecule was up to 50 times more effective than the natural product against several bacterial strains. Additionally, they found that the molecule was often more effective against resistant bacterial strains than it was against nonresistant strains.
“An exciting additional aspect of this work was that we identified that these molecules may function by inhibiting multiple biosynthetic pathways directly or indirectly,” says Pierce. “This means that bacteria may have difficulty developing resistance to potential drugs developed from these molecules.”
While more work is needed, Pierce hopes that JJM-35 and similar compounds can be used as tools to study other Gram-positive bacteria and provide a platform for the development of a novel class of anti-infective agents.
“At this point, we have a chemical scaffold – a starting piece of the puzzle. We know that this piece is effective, and so right now all efforts are focused on evaluating the properties of these molecules and their in vivo efficacy,” says Pierce. “The hope is that we can build upon this scaffold to create drugs that are effective against MRSA and other resistant bacteria at a time of dire need for antimicrobial development while also increasing the spectrum of activity.”
Learn more: New Compound Effective Against Drug-Resistant Pathogens Could Lead to Next-Generation Antibiotics
The Latest on: Antimicrobial development
[google_news title=”” keyword=”antimicrobial development” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Antimicrobial development
- Dr. James Gill's insights on combating the global crisis of antimicrobial resistanceon April 27, 2024 at 12:42 am
Dr. James Gill, a Clinical Lecturer at the University of Warwick and a practicing GP, will attend a pivotal event hosted at the House of Lords on Monday (April 29) focused on combating the global ...
- Experts develop way to harness CRISPR technology to deal with antimicrobial resistanceon April 26, 2024 at 3:10 pm
Antimicrobial resistance (AMR) is continuing to increase globally, with rates of AMR in most pathogens increasing and threatening a future in which every day medical procedures may no longer be ...
- Vaccines have a crucial role in tackling antimicrobial resistanceon April 26, 2024 at 10:04 am
Antimicrobial resistance is a leading cause of death and disability worldwide. In 2019, it caused over 1 million deaths globally and was linked to almost 5 million.
- Vancomycin May Be Losing Strength Against Common Deadly Infectionon April 26, 2024 at 4:46 am
Now, a new study suggests that the leading antibiotic used to fight it, vancomycin, may be losing potency against this killer. The second-line drug is fidaxomicin (Dificid). “If antimicrobial ...
- Superbugs could lower your life expectancy by nearly 2 years, report says. What to know about antimicrobial resistanceon April 25, 2024 at 5:25 pm
Public Health Emergency, a group of international political, public health, and biomedical leaders warns of another menace to human life that could also trigger economic loss. Antimicrobial ...
- Researchers systematically investigate efficacy of CRISPR antimicrobial agentson April 25, 2024 at 1:28 pm
The antimicrobial potential of CRISPR-Cas systems is promising, yet how to best design or implement CRISPR nucleases remains poorly understood. An international team led by the Helmholtz Institute for ...
- Benzalkonium Chloride Market Poised for Growth, Expected to Reach US$ 2,267.3 Million by 2034, with a CAGR of 2.00%on April 24, 2024 at 8:03 pm
The benzalkonium chloride market is set to experience substantial growth, with a valuation of US$ 1,856.2 million in 2024. It is projected to reach US$ 2,267.3 million by 2034, reflecting a CAGR of 2.
- F.D.A. Approves Antibiotic for Increasingly Hard-to-Treat Urinary Tract Infectionson April 24, 2024 at 1:45 pm
Pivmecillinam, which has been used in Europe for decades, will become available next year to women 18 and older.
- Pomegranate power: Unlocking sustainable antimicrobial solutions from peelson April 19, 2024 at 11:05 am
Pomegranates, known for their rich phenolic content, have been explored for their potential as natural antimicrobials. The research focuses on the peel, which contains a high concentration of these ...
via Bing News